ArticleDiscover oncology2026
Multi-omics analysis of key lipid metabolism-related genes involved in the anti-hepatocellular carcinoma effect of dihydroartemisinin.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify the candidate genes of dihydroartemisinin (DHA) in acting against hepatocellular carcinoma (HCC), as well as its association with lipid metabolism-related genes (LMRGs), thereby providing a basis for the application of DHA in anti-HCC therapy.
methodsPotential candidate genes of DHA were predicted using databases. Differentially expressed genes (DEGs) were screened from HCC datasets in the Gene Expression Omnibus (GEO) database. Common candidate genes of DHA and HCC were obtained through Weighted Gene Co-expression Network Analysis (WGCNA) and intersection analysis. Protein-protein interaction (PPI) networks and Gene Ontology (GO) or Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to decipher functional pathways. Candidate genes were screened using ensemble models, followed by validation via SHapley Additive exPlanations (SHAP) analysis. Integrating data from LMRG databases, along with gene expression and survival analyses, the key genes were finally identified.
resultsA total of 306 candidate genes of DHA and 45 common candidate genes of DHA and HCC were obtained. These common candidate genes were enriched in pathways such as the p53 signaling pathway and cell cycle. 10 candidate genes, including cytochrome P450 1A2 (CYP1A2), cytochrome P450 2C19 (CYP2C19), sex hormone-binding globulin (SHBG), insulin-like growth factor 1 (IGF1), sulfotransferase family 1E member 1 (SULT1E1), cyclin-dependent kinase 1 (CDK1), aurora kinase A (AURKA), aldo-keto reductase family 1 member C3 (AKR1C3), cyclin A2 (CCNA2), and heat shock protein 90 alpha family class B member 1 (HSP90AB1) were screened out, with the model achieving an area under the receiver operating characteristic curve (AUC) of 0.961. Among these candidate genes, CYP1A2 and CYP2C19 contributed the most to the model. Three key LMRGs (CYP1A2, CYP2C19, and AKR1C3) were identified, which exhibited abnormal expression in HCC tissues and were associated with the survival of HCC patients.
conclusionBased on analyses of public databases and computational predictions, DHA may exert anti-HCC effects by regulating the p53 signaling pathway, cell cycle progression, and the LMRGs. However, these potential regulatory mechanisms require further experimental validation to confirm their biological relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.